drugset / Trial / NCT02737020

Rhodiola Rosea in Adults With Attention Deficit/Hyperactivity Disorder

NCT02737020

Phase 4 Unknown 60 enrolled Hospital de Clinicas de Porto Alegre
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study evaluates the use of Rhodiola rosea in the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in adults. Half of participants will receive Rhodiola rosea, while the other half will receive placebo.

Timeline

Start
2016-04
Primary completion
2021-03
Completion
2021-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Rhodiola Traditional medicine (herbal / TCM) 200 mg